News
Two NIH Technology Transfer experts will be speaking at the Biotechnology Innovation Organization 2025 International Convention taking place in Boston, June 16-19, 2025, with pre-conference sessions taking place June 14-15. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer
The National Institute of Dental and Craniofacial Research (NIDCR) at the NIH has a great non-exclusive license opportunity available to commercialize a novel adeno-associated virus termed “44-9” (AAV44-9) vector for gene therapy. AAV44-9 based vectors have high gene transfer activity in many cell
Attend the FLC’s Using Valuations in Technology Transfer webinar to hear from NIH Office of Technology Transfer’s (OTT’s) Steve Ferguson on why using valuations is a good start to gathering information needed at various stages of technology transfer. Topics covered include why valuation is needed
Comirnaty®, colloquially known as the Pfizer vaccine, is a messenger RNA (mRNA) vaccine indicated for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This vaccine by BioNTech/Pfizer received full FDA approval on August 23, 2021, after